BLINKLAB LIMITED - News & Media

Market Cap $21.12M Add to my watchlist

Healthcare Medical Devices

BlinkLab Limited (ASX: BB1) is a trailblazer in digital healthcare, leveraging AI and... BlinkLab Limited (ASX: BB1) is a trailblazer in digital healthcare, leveraging AI and machine learning in mobile applications to revolutionise neurodevelopmental condition diagnosis like ASD and ADHD. Born from extensive research at Princeton University, BlinkLab offers early detection and effective intervention solutions through its smartphone-based diagnostic platform. The company is committed to improving mental health care globally, starting with the youngest patients.More

Corporate Spotlight

BlinkLab Limited (ASX: BB1) is a trailblazer in digital healthcare, leveraging AI and machine learning in mobile applications to revolutionise neurodevelopmental condition diagnosis like ASD and ADHD.
View the full Corporate Spotlight

PROF. WANG DISCUSSES BLINKLAB'S AI APP FOR AUTISM

Articles & Videos

BlinkLab partnership with US smart-tech Turning Pointe raises hopes for autism kids

BlinkLab partners with US-based Turning Pointe Autism Foundation for clinical study ahead of its FDA registration study later in the year

02 May 2024 11:19 (AEST)

Why Princeton Professor rates BlinkLab's autism & ADHD screening app

In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and potential of BlinkLab's (ASX:BB1) AI-driven smartphone app, designed to screen for autism and ADHD.

30 Apr 2024 15:11 (AEST)

BlinkLab up as much as 50% on debut

BlinkLab (ASX:BB1) has traded up as much as 50 per cent on listing on the ASX this morning, breaking the ASX IPO drought.

04 Apr 2024 14:09 (AEDT)

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to detect autism and ADHD. It’s listing on the ASX next Thursday (April 4) under the code BB1. BlinkLab’s development is being led by chair Brian Leedman - a founder of ResApp Health - the cough analysis app sold to Pfizer two years ago in a $179 million deal.

28 Mar 2024 08:54 (AEDT)

(20min delay)
Last 37.0¢		Change -0.005(1.33%)		Mkt cap ! $21.12M

Open	High	Low	Value	Volume
38.0¢	39.0¢	37.0¢	$124.8K	333.0K

Buyers (Bids)

No.	Vol.	Price($)
7	446702	37.0¢

Sellers (Offers)

Price($)	Vol.	No.
38.0¢	995	1

View Market Depth

No.	Vol.	Price($)
7	446702	0.370
1	20000	0.360
1	5000	0.355
6	151356	0.350
1	10005	0.340

Price($)	Vol.	No.
0.380	995	1
0.390	32662	3
0.395	29752	3
0.400	60792	4
0.405	82450	3

Last trade - 16.10pm 14/05/2024 (20 minute delay)


Last 37.5¢		Change -0.005 ( 0.00 %)
Open	High	Low	Volume
38.5¢	38.5¢	37.0¢	184832
Last updated 15.46pm 14/05/2024 ?

BB1 (ASX) Chart